2021
1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
Papadopoulos K, Yap T, Piha-Paul S, Lorusso P, Hu-Lieskovan S, Shepherd C, Marshall S, Holz J, Poon E, Grabowska U, Kayitalire L. 1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies. Annals Of Oncology 2021, 32: s864-s865. DOI: 10.1016/j.annonc.2021.08.1417.Peer-Reviewed Original Research
2018
422P First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies
Lorusso P, Chawla S, Bendell J, Shields A, Shapiro G, Rajagopalan P, Cyris C, Bruns I, Mei J, Souza F, Rasco D, Eder J, Tolcher A. 422P First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies. Annals Of Oncology 2018, 29: viii138. DOI: 10.1093/annonc/mdy279.410.Peer-Reviewed Original ResearchA phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.
Lakhani N, LoRusso P, Hafez N, Krishnamurthy A, O'Rourke T, Kamdar M, Fanning P, Zhao Y, Jin F, Wan H, Pons J, Randolph S, Messersmith W. A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma. Journal Of Clinical Oncology 2018, 36: 3068-3068. DOI: 10.1200/jco.2018.36.15_suppl.3068.Peer-Reviewed Original Research
2011
Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
Sarantopoulos J, Lenz H, LoRusso P, Shibata S, Kummar S, Mulkerin D, Ramanathan R, Mita M, O'Rourke P, Remick S, Goel S, Gutierrez M, Ramalingam S, Murgo A, Davies A, Mani S, Boni J, Shapiro M, Ivy S, Takimoto C. Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. Journal Of Clinical Oncology 2011, 29: 3072-3072. DOI: 10.1200/jco.2011.29.15_suppl.3072.Peer-Reviewed Original ResearchFirst-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
Sosman J, Adjei A, LoRusso P, Michael S, Dy G, Bowditch A, Chmielowski B, Lee S, Walker R, Faucette S, Izmailova E, Bozon V, Ribas A. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. Journal Of Clinical Oncology 2011, 29: tps145-tps145. DOI: 10.1200/jco.2011.29.15_suppl.tps145.Peer-Reviewed Original Research
2010
381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies
Tolcher A, Papadopolous K, Patniak A, Heath E, Weise A, Prokop T, Morrone S, Zanghi J, Keer H, LoRusso P. 381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies. European Journal Of Cancer Supplements 2010, 8: 121. DOI: 10.1016/s1359-6349(10)72088-7.Peer-Reviewed Original ResearchA phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.
Brana I, LoRusso P, Baselga J, Heath E, Patnaik A, Gendreau S, Laird A, Papadopoulos K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. Journal Of Clinical Oncology 2010, 28: 3030-3030. DOI: 10.1200/jco.2010.28.15_suppl.3030.Peer-Reviewed Original Research
2008
Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies
Krishnamurthi S, LoRusso P, Goncalves P, Fox F, Rowinsky E, Schwartz J, Youssoufian H. Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies. Journal Of Clinical Oncology 2008, 26: 14630-14630. DOI: 10.1200/jco.2008.26.15_suppl.14630.Peer-Reviewed Original Research
2005
The effect of food on the pharmacokinetics of BMS-275183, a novel oral taxane, in patients with advanced solid malignancies
Woo M, Broker L, Pilat M, Malburg L, Cohen M, Griffin T, Valdivieso M, Giaccone G, Lorusso P. The effect of food on the pharmacokinetics of BMS-275183, a novel oral taxane, in patients with advanced solid malignancies. Journal Of Clinical Oncology 2005, 23: 2053-2053. DOI: 10.1200/jco.2005.23.16_suppl.2053.Peer-Reviewed Original Research